Trading of shares in Eqology AS

News 19.11.20

Cancellation of extraordinary general meeting in EQOLOGY AS – withdrawal of contemplated offer to shareholders

Reference is made to the notice published on 11 November 2020 that called for a general meeting in Eqology AS (“Eqology”) to resolve a de-listing of Eqology’s shares from NOTC during December 2020. ImmunoPharma AS (ImmunoPharma), which controls more than 2/3 of the outstanding shares in Eqology, requested a de-listing of Eqology’s shares. Due to feedback from certain minority shareholders, ImmunoPharma has requested the board of Eqology to cancel the extraordinary general meeting called for at Friday 20 November at 1 pm CET. Consequently, and in light of ImmunoPharma’s shareholding, the board of Eqology has today decided that said extraordinary general meeting is cancelled.

ImmunoPharma has further informed the board of Eqology that the contemplated offer for Eqology shares set forth in the notice on 6 November 2020 is withdrawn, and that ImmunoPharma will consider to offer to buy outstanding shares in Eqology following Eqology’s adoption of the annual accounts for 2020.

For questions regarding the cancellation of the general meeting, contact:

Roar Arnstad
CEO
E-mail: roar.arnstad@eqology.no

Christian Espeseth
Chairman of the board

arrowCancellation of extraordinary general meeting in EQOLOGY AS


News 12.11.20

Call for extraordinary general meeting

arrowCall for extraordinary general meeting

Innkalling Ekstra ordinær Generalforsamling – Eqology AS – 20 november 2020

arrowInnkalling Ekstra ordinær Generalforsamling – Eqology AS – 20 november 2020

Offer to shareholders in Eqology

arrowOffer to shareholders in Eqology


News 30.10.19

Eqology AS’s President Research, Development and Communication of health concepts Børre Gjersvik second-largest shareholder

Eqology AS’s President Research, Development and Communication of health concepts Børre Gjersvik has today acquired 7,000,000 shares in Eqology AS. He previously had 4,152,930 shares. This means that he now has 11,152,930 shares in Eqology AS, which means that he has become the company’s second-largest shareholder with 10, 2% of the company’s shares. In this connection, he states that he has great faith in the future of the company and its growth potential.


Shares issued by Eqology AS are registered in the Norwegian VPS with ISIN NO0010585144. Last trading price of the shares will be reported on the Norwegian OTC-list (notc.no).

Norne Securities AS facilitates the trading of shares in Eqology
In order to register your interest to buy or sell shares, we kindly ask you to fill in and return, the client form below (for Norwegian residents), to the below e-mail with information on your interest to buy or sell shares (including price and volume). You will then be contacted by Norne Securities.

When Norne Securities is able to match a buyer and a seller, Norne Securities will close the transaction between the parties after further instructions.

The trading fee to Norne Securities:
0,30% per trade for buyer and seller (minimum fee is NOK 350).

Non-residents cannot register directly with Norne Securities.
Non-residents must register as an equity client with a domestic bank or broker which again contact a Norwegian counterpart. Unfortunately, not all banks or brokers offer OTC registered stocks. Nordic residents can contact Nordea or Danske bank in order to trade shares in Eqology AS.

Contact:
Svein Erik Strand Tønnesen
Corporate Finance
Mobile: +47 97 07 96 46
E-mail: set@norne.no

Quarterly, Half Year and Annual report Eqology AS:

arrowQuarterly update Eqology AS Q3 2020 EN

arrowEQ First Half Year Report 2020

arrowEQ Annual Report 2019

arrowEQ Annual Report 2018

arrowQuarterly update Eqology AS Q3 2018 EN

arrowQuarterly update Eqology AS Q3 2018 NO

 

Attachments (for Norwegian residents):

arrowAgreement for corporate clients (foretakskunde)

arrowAgreement for private clients (privatkunde)

arrowNorne Handels og sporrefullmakt for foretakskunder